全身性強皮症– tag –

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial Dinesh Khanna, Celia J F Lin, Daniel E Furst, Jonathan Goldi...

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-b...

Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, para...

Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, ...

Cyclophosphamide versus Placebo in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel ...

このページでは患者さん向けに、膠原病・自己免疫疾患について、わかりやすく説明します。 膠原病とは、自分の「免疫」が「自己」を攻撃する疾患　のこと。 膠原病とは...

このページでは患者さん向けに、膠原病・自己免疫疾患について、わかりやすく説明します。 膠原病とは、自分の「免疫」が「自己」を攻撃する疾患　のこと。 膠原病とは...

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial Dinesh Khanna, Celia J F Lin, Daniel E Furst, Jonathan Goldi...

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-b...

Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, para...

Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, ...

Cyclophosphamide versus Placebo in Scleroderma Lung Disease Donald P. Tashkin, Robert Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel ...